NBIX financials
Neurocrine Biosciences (NBIX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
NBIX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $2.86B | $2.81B | $619.10M | $478.60M | 4.67 |
| 2024 | $2.36B | $2.32B | $570.50M | $341.30M | 3.29 |
| 2023 | $1.89B | $1.85B | $250.90M | $249.70M | 2.47 |
| 2022 | $1.49B | $1.47B | $249.00M | $154.50M | 1.56 |
| 2021 | $1.13B | $1.12B | $102.50M | $89.60M | 0.92 |
| 2020 | $1.05B | $1.04B | $163.00M | $407.30M | 4.16 |
- NBIX revenue was $2.86B in fiscal 2025, net income $478.60M.
Updated 2026-11-02 23:14 UTC